This inventor holds 1 USPTO granted patent. Top assignees: Inotrem, Inserm (Institut National De La Santé Et De La Recherche Médicale), Universite Paris Cité. Active years: 2026.
Company Filing History:
1 out of 3 
1 out of 16 
1 out of 72 
Years Active: 2026
Title: Thomas Mintz: Innovator in Sickle Cell Disease Treatment
Introduction
Thomas Mintz is a notable inventor based in Paris, France. He has made significant contributions to the field of medical research, particularly in the treatment of sickle cell disease. His innovative approach has led to the development of a unique patent that addresses critical health issues faced by patients.
Latest Patents
Thomas Mintz holds a patent titled "TREM-1 Inhibitors for the Treatment of Vaso-Occlusions and Tissue Injuries in Patients Suffering from Sickle Cell Disease." This patent represents a breakthrough in the management of complications associated with sickle cell disease, showcasing his commitment to improving patient outcomes.
Career Highlights
Throughout his career, Thomas Mintz has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université Paris Cité. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Thomas has collaborated with notable colleagues, including Pierre-Louis Tharaux and Olivia Lenoir. These partnerships have enriched his research and expanded the impact of his innovations in the medical community.
Conclusion
Thomas Mintz is a distinguished inventor whose work in the treatment of sickle cell disease has the potential to transform patient care. His dedication to innovation and collaboration underscores the importance of research in addressing complex health challenges.